Drugs / ABCI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05802264 | Mar 2023 → Dec 2025 overdue | cystic fibrosis | Cystetic Medicines, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABCI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05802264 ↗ |
| Route | Inhaled | “via oral inhalation” NCT05802264 ↗ |